Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Management of Postauricular Benign Tumors

Assessment and Diagnosis

  • Initial evaluation should include MRI and audiological assessment to determine tumor size, location, and impact on surrounding structures 2
  • Tumors are classified using the Koos grading system (I-IV) based on size and extension, which guides treatment decisions 2, 3
  • Multidisciplinary tumor board discussion is recommended for comprehensive evaluation, especially for medium-sized tumors 1

Management Algorithm Based on Tumor Size and Symptoms

  • Observation with serial MRI and audiological monitoring is the management of choice for small asymptomatic tumors (evidence level III, recommendation level C) 2, 1
  • Annual MRI follow-up for 5 years is recommended, with longer intervals thereafter if stable 3, 1
  • Stereotactic radiosurgery (SRS) is an alternative to observation to stop tumor growth and preserve long-term nerve function (evidence level II, recommendation level B) 2, 1
  • Surgery is not recommended for small asymptomatic tumors due to high risk of functional deterioration (up to 50%, evidence class III, recommendation level C) 2

Surgical Approaches

  • If surgery is indicated, treatment at a high-volume center is recommended since surgical experience affects outcomes (evidence class IV) 2, 1

Follow-up Recommendations

  • Annual MRI and audiometry for 5 years, then every 2 years if stable, for conservatively managed, radiated, and incompletely resected tumors 3, 6
  • For gross total resection, MRI controls postoperatively and after 2, 5, and 10 years are sufficient 3, 6
  • Shorter follow-up intervals (6-12 months) are recommended for patients with neurofibromatosis type 2 (NF2) 5

Special Considerations

  • For patients with NF2 and bilateral vestibular schwannomas, bevacizumab shows positive effects on hearing and tumor growth (evidence class II, recommendation level B) 5

Treatment Pitfalls and Caveats

  • Risk for tumor regrowth after subtotal resection increases with residual tumor volume 1
  • Even after 5 years of stability, 7.2% of tumors may exhibit growth, necessitating long-term follow-up 3
  • Facial nerve preservation should be prioritized during surgical management, as facial nerve palsy can lead to significant complications including exposure keratopathy and corneal damage 3
  • Pseudoprogression on imaging after SRS should be evaluated by specialists from multiple disciplines to avoid unnecessary interventions 2